<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32870032</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7-8</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Juvenile amyotrophic lateral sclerosis with complex phenotypes associated with novel <i>SYNE1</i> mutations.</ArticleTitle><Pagination><StartPage>576</StartPage><EndPage>578</EndPage><MedlinePgn>576-578</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1813312</ELocationID><Abstract><AbstractText>Mutations in <i>SYNE1</i> have been originally described to cause a slowly progressive, pure cerebellar ataxia (spinocerebellar ataxia, autosomal-recessive 8; SCAR8). Notably, recent studies revealed that affected patients with <i>SYNE1</i>-associated ataxia can present with complex phenotypes rather than pure cerebellar ataxia, including motor neuron and brainstem dysfunctions. We herein report a Japanese patient diagnosed with juvenile amyotrophic lateral sclerosis (ALS) with a complex phenotype, who carried compound heterozygous pathogenic variants in <i>SYNE1</i>. Of the variants, one was a novel frameshift variant and the other was a nonsense variant previously reported as pathogenic for SCAR8. The patient showed an early age at onset with a relatively slow but progressive course of ALS, accompanied by cognitive decline. Our findings suggest that the clinical spectrum of patients carrying pathogenic <i>SYNE1</i> variants is broader than expected, and <i>SYNE1</i> variants should be considered in patients diagnosed with juvenile ALS, even without prominent cerebellar ataxia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naruse</LastName><ForeName>Hiroya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishiura</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsui</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsukawa</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toda</LastName><ForeName>Tatsushi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Shoji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Genomics, International University of Health and Welfare, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C415465">SYNE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Juvenile amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">SYNE1 mutation</Keyword><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32870032</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1813312</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>